Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.42 |
| ▸ | SIK1 | P57059 | 2/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.41 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666423 | 0.91 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12694695 | 0.88 | MEN1 (0.48) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12415705 | 0.87 | MEN1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12415693 | 0.86 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2189538 | 0.84 | HPGD (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2666329 | 0.82 | MEN1 (0.47) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2666380 | 0.81 | HPGD (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12415795 | 0.78 | GABRA1 (0.52) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL19467894 | 0.77 | GABRA1 (0.63) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12415691 | 0.77 | FGFR1 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278460-B2 | Substituted benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | GABRA1 6/4885GABRG2 14/4885GABRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.